Share

As your body ages, increasing amounts of your cells enter a state of cellular senescence. These cells no longer divide or support the tissues of which they are part; instead, they emit a cocktail of harmful chemical signals that encourage other nearby cells to also enter the same senescent state.

The presence of senescent cells contributes to decreasing tissue function, increases chronic inflammation, and can even raise the risk of cancer and other age-related diseases.

Senescent cells normally destroy themselves via a programmed process called apoptosis and are removed by the immune system; however, the immune system declines with age, and increasing numbers of these senescent cells escape this disposal process and accumulate.

By the time people reach old age, significant numbers of these senescent cells have built up in their bodies, causing inflammation and damage to surrounding cells and tissues. These senescent cells are one of the hallmarks of aging and a key process in the progression of aging and age-related diseases [1-2].

One proposed way to deal with this problem is to remove these senescent cells by causing them to go into apoptosis using therapies known as senolytics.

Macrophages with markers of cellular senescence may not be senescent 

Researchers commonly determine the presence of senescent cells through the use of the p16ink4a (p16) and β-galactosidase biomarkers. Senescent cells are known to exhibit both of these biomarkers, but it seems that they are not the only cells that do this, and the concern is that therapies that target these biomarkers may also be removing cells that are not senescent.

A study was published recently, and it shows that some cells that are not necessarily senescent share these two biomarkers [3]. This new study is by the same research team that investigated cellular senescence in the immune system last year with a focus on macrophages [4].

So, could this mean that older people have a partially senescent macrophage population, or does it mean that these cells are not harmful and just exhibit some of the same markers that senescent cells do?

This new study suggests that the latter may be the case, although it has not yet been determined if the macrophages exhibiting these commonly shared biomarkers are harmful.

So is this an issue for senolytics?

Fortunately, we are aware of no research group developing senolytics that target β-galactosidase. The use of β-galactosidase is limited to assessing the presence and numbers of senescent cells but is not actually the target of therapies.

However, p16 is a potential issue, as at least one company, Oisin Biotechnology (we interviewed its CEO here) does use this biomarker to target senescent cells. Its approach uses target genes and their level of expression in order to target cells for destruction. Oisin will no doubt be doing its due diligence in determining the effect of removing p16-positive macrophages as part of its ongoing development process.

That said, one of the first proof-of-concept studies used p16 as the target for senescent cell removal, and positive health results were seen [5]. So, it is worth bearing in mind that, in this case, p16 cells, regardless of the source, were removed in a broad stroke in this study, yet positive benefits were observed.

Therefore, it may be that case that removing them is not a significant problem, and earlier studies strongly suggest that removing senescent cells is beneficial, even taking into account the risk of removing non-senescent cells.

Conclusion

The paper’s authors conclude that the importance of senescent cells in the aging process and removing senescent cells is not in question, and their findings do not suggest that developing senolytics is a bad idea.

The points raised here are that we need to better refine how we identify senescent cells and that we need to improve our understanding of how to determine if a cell is senescent. Therefore, we need to develop better biomarkers to identify senescent cells.

Considering the research community’s intense focus on senescent cells and the considerable funding behind the development of senolytics, those gaps in our knowledge will likely not remain in place for long.

Given the pace of progress in this particular area, it is reasonable to believe that such issues may be resolved in the near future once more studies are concluded.

Literature

[1]  López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. Cell, 153(6), 1194-1217.

[2]  van Deursen, J. M. (2014). The role of senescent cells in ageing. Nature, 509(7501), 439-446.

[3] Hall, B. M., Balan, V., Gleiberman, A. S., Strom, E., Krasnov, P., Virtuoso, L. P., … & Leonova, K. I. (2017). p16 (Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. Aging.

[4] Hall, B. M., Balan, V., Gleiberman, A. S., Strom, E., Krasnov, P., Virtuoso, L. P., … & Leonova, K. (2016). Aging of mice is associated with p16 (Ink4a)-and β-galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells. Aging (Albany NY), 8(7), 1294.

[5] Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., Van De Sluis, B., … & Van Deursen, J. M. (2011). Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature, 479(7372), 232.

 

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic as well as attending various medical industry conferences. In 2019 he was listed in the top 100 journalists covering biomedicine and longevity research in the industry report – Top-100 Journalists covering advanced biomedicine and longevity created by the Aging Analytics Agency. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, and, Keep me Prime, and New Economy Magazine. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project. In 2015 he led the Major Mouse Testing Program (MMTP) for the International Longevity Alliance and in 2016 helped the team of the SENS Research Foundation to reach their goal for the OncoSENS campaign for cancer research.
Write a comment:

*

Your email address will not be published.

© 2020 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD